Tretiva
Tretiva Price range: $ 41,00 through $ 792,00
Back to products
Tricor
Tricor Price range: $ 55,00 through $ 509,00

Trial ED Pack

$ 60,00

The Trial ED Pack is a specially curated selection of the most effective medications designed to treat erectile dysfunction. This versatile set allows men to compare different formulations to find the specific treatment that works best for their body. Each pack includes a variety of high-quality options known for enhancing blood flow and improving sexual performance. It is an ideal solution for those seeking to restore their confidence and maintain a satisfying intimate life. By testing various proven medications, you can determine which one provides the most reliable and long-lasting results for your needs.

Active substance: Sildenafil, Tadalafil, Vardenafil
SKU: Trial ED Pack Categories: , ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

The Trial ED Pack belongs to a class of pharmacological options containing phosphodiesterase type 5 (PDE5) inhibitors designed to treat erectile dysfunction (ED). These combination sample collections typically contain individual therapeutic doses of distinct active ingredients, such as sildenafil, tadalafil, or vardenafil, allowing a clinician to determine which agent yields optimal clinical response. In the United States, all component medications within the pack are classified as prescription-only drugs and must be dispensed in accordance with federal and state laws following evaluation by a licensed healthcare professional.

Because each active constituent possesses unique pharmacokinetic parameters, understanding proper administration, metabolic timing, and safety profiles is essential for safe usage. This informational overview outlines the clinical characteristics, interaction warnings, and monitoring parameters associated with the active substances in the Trial ED Pack.

Parameter Clinical Description
Drug Name Trial ED Pack
Active Ingredients Sildenafil citrate, Tadalafil, Vardenafil hydrochloride (varies by pack composition)
Therapeutic Class Phosphodiesterase Type 5 (PDE5) Inhibitors
Route of Administration Oral
Primary Purpose Management of erectile dysfunction in adult men
Prescription Status Prescription Only (Rx)
Storage Conditions Store at 20°C to 25°C (68°F to 77°F) away from moisture

Clinical Profile and Pharmacological Properties

How the drug works

The active compounds provided in the Trial ED Pack–specifically sildenafil, tadalafil, and vardenafil–function through the selective inhibition of the enzyme phosphodiesterase type 5 (PDE5). During sexual stimulation, nitric oxide is released from local nerve endings and endothelial cells in the corpus cavernosum of the penis. Nitric oxide activates guanylate cyclase, increasing intracellular levels of cyclic guanosine monophosphate (cGMP). cGMP promotes smooth muscle relaxation and enhanced arterial blood influx into penile tissues. By inhibiting PDE5, these agents prevent the enzymatic degradation of cGMP, preserving vascular relaxation and facilitating an erectile response. Sexual stimulation is required; these medications do not initiate erections independently without underlying physiological arousal.

What it’s used for

The Trial ED Pack is indicated for the management of erectile dysfunction (ED) in adult men, defined as the persistent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance. Off-label use of specific component agents (such as sildenafil or tadalafil) occurs in non-combination settings for pulmonary arterial hypertension or benign prostatic hyperplasia; however, sample packs intended for ED are strictly reserved for erectile care. A medical provider evaluates patient suitability based on cardiovascular status, symptom severity, and concurrent health conditions before selecting appropriate dosages of the individual agents included in the bundle.

Dosing schedule

Dosage schedules vary depending on which individual pill from the pack is selected for a given administration. Component medications must never be taken simultaneously; only one dose of a single agent should be ingested within a 24-hour window. Sildenafil and vardenafil are typically administered orally approximately 60 minutes prior to anticipated sexual activity, with efficacy lasting roughly 4 to 6 hours. Tadalafil may be taken 30 to 60 minutes prior to activity, offering an extended therapeutic window of up to 36 hours. Dosing must follow exact instructions provided by the prescribing physician, taking into account liver function, kidney health, and baseline cardiovascular tolerance.

What happens in the body

Pharmacokinetic properties differ distinctly among the component drugs within the trial kit. Sildenafil is rapidly absorbed after oral administration, reaching maximum plasma concentration within 30 to 120 minutes, with a terminal elimination half-life of approximately 4 hours. Vardenafil exhibits a similar absorption profile, reaching peak concentration in about 60 minutes with a half-life of 4 to 5 hours. Tadalafil demonstrates prolonged absorption and a significantly longer elimination half-life of approximately 17.5 hours, maintaining plasma concentration over an extended duration. All three compounds undergo hepatic metabolism primarily mediated by the cytochrome P450 3A4 (CYP3A4) enzyme system and are eliminated predominantly as inactive metabolites via feces and urine.

Safety, Interactions, and Practical Use

Compatibility with other medicines

PDE5 inhibitors exhibit critical drug-drug interactions that require strict clinical oversight. Concomitant administration with organic nitrates (such as nitroglycerin, isosorbide mononitrate, or isosorbide dinitrate) or nitric oxide donors (alkyl nitrites) is strictly contraindicated due to severe, potentially life-threatening systemic hypotension. Co-administration with alpha-adrenergic blockers (e.g., tamsulosin, doxazosin) may lead to symptomatic blood pressure drops, necessitating stabilized alpha-blocker therapy prior to initiating PDE5 therapy. Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, and ritonavir, significantly increase plasma concentrations of PDE5 inhibitors, requiring dosage reductions. Antihypertensive agents may demonstrate additive blood pressure-lowering effects when combined with these medications.

Adverse reactions

Adverse reactions associated with PDE5 inhibitors are generally mild to moderate and transient in nature, resulting from systemic vasodilatory activity. The most frequently reported side effects include headache, facial flushing, dyspepsia, nasal congestion, dizziness, and back pain (notably more pronounced with tadalafil due to tissue distribution). Visual disturbances, such as transient blue-green color tinge (cyanopsia) or light sensitivity, occur predominantly with sildenafil owing to mild inhibition of retinal PDE6. Less common but severe adverse events include sudden decrease or loss of hearing, sudden vision loss attributed to non-arteritic anterior ischemic optic neuropathy (NAION), and priapism.

Important precautions

Prior to prescribing PDE5 inhibitors, a complete cardiovascular evaluation is mandatory, as sexual activity carries an inherent cardiac risk for patients with pre-existing heart disease. These medications are not recommended for individuals with severe heart failure, recent myocardial infarction or stroke (within 6 months), unstable angina, or severe hepatic impairment. Patients with anatomical penile deformities (Peyronie’s disease) or conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia) require cautious evaluation. Use in pediatric populations is not established. Elderly patients may exhibit reduced clearance, warranting conservative initial dosage titration under professional supervision.

What to avoid while taking it

High-fat meals significantly delay the rate of absorption and reduce peak plasma concentrations of sildenafil and vardenafil, potentially delaying onset of therapeutic effect. Tadalafil absorption remains largely unaffected by food intake. Moderate to heavy alcohol consumption should be avoided when taking any PDE5 inhibitor; ethanol possesses intrinsic vasodilatory properties that, when combined with PDE5 inhibition, increase the risk of orthostatic hypotension, dizziness, tachycardia, and headache. Grapefruit juice inhibits CYP3A4 metabolism and must be avoided to prevent unpredictable drug accumulation.

Red flags

Immediate medical attention is required if a patient experiences an erection lasting longer than 4 hours (priapism), as delayed treatment can result in permanent erectile tissue damage and irreversible erectile dysfunction. Emergency care must be sought immediately if sudden loss of vision occurs in one or both eyes, or if sudden decrease or loss of hearing accompanied by tinnitus or dizziness develops. Patients experiencing chest pain, severe dizziness, or shortness of breath during sexual activity should cease activity immediately and contact emergency services, informing healthcare staff of PDE5 inhibitor ingestion.

Missed dose

Because PDE5 inhibitors in sample packs are taken on an as-needed basis prior to anticipated sexual activity, rigid daily dosing schedules are generally not applicable. If a scheduled daily regimen (such as low-dose tadalafil) is prescribed and a dose is missed, it should be taken as soon as remembered on that day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Patients must never double doses or take multiple pills from the trial pack at the same time to make up for a missed dose.

Storage and expiration

Medications within the Trial ED Pack should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F), with temporary excursions permitted between 15°C and 30°C (59°F to 86°F). Keep all tablets in their original blister packaging protected from moisture, excessive heat, and direct light. Store securely out of reach of children and pets. Do not use any component after the expiration date clearly stamped on the packaging. Unused or expired medications should be disposed of via authorized community take-back programs rather than flushed down household drains.

Frequently Asked Questions

How should I decide which tablet from the Trial ED Pack to try first?

The order in which you evaluate individual agents should be determined in consultation with your prescribing healthcare provider. Factors such as planned activity timing, meal schedule, and prior tolerance to vasodilatory medications will guide whether a short-acting agent (like sildenafil or vardenafil) or a longer-acting agent (like tadalafil) is most appropriate for initial trial.

Can I take two different pills from the pack on the same day to see which works better?

No. Combining different PDE5 inhibitors simultaneously or taking multiple doses within a 24-hour period is extremely dangerous. Doing so significantly increases the risk of severe hypotension, priapism, and cardiovascular complications. Always allow a complete washout period–typically at least 24 to 48 hours depending on the agent–before trying a different medication from the pack.

What should I do if a specific component medication does not produce an adequate response?

A single unpromising trial does not necessarily indicate treatment failure. Clinical response can be influenced by meal composition, alcohol intake, anxiety, or timing. Healthcare providers frequently recommend trying a specific agent on several distinct occasions under optimal conditions before declaring it ineffective or switching to a different pill in the pack.

Is it safe to drive after taking a medication from the trial pack?

PDE5 inhibitors can occasionally cause dizziness, lightheadedness, or transient visual disturbances such as blue-tinted vision or blurriness. You should assess how your body responds to an individual tablet before operating motor vehicles or operating dangerous machinery.

How long must I wait between testing different sample tablets from the pack?

Because tadalafil has an extended elimination half-life of approximately 17.5 hours and remains active in the body for up to 36 hours, a washout window of at least 48 hours is recommended after taking tadalafil before trying another PDE5 inhibitor. For sildenafil or vardenafil, a minimum 24-hour interval is generally advised, subject to specific instructions from your clinician.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

100mg+20mg+20mg

Package

15 pills

Ενεργός Ουσία

,

,